Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
NCT01044225 · Bart Neyns · PHASE2 · terminated · last registry update 2012-03-22 · Glioblastoma · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end their support to the trial” | Open Targets' class: another study | Registry record, Bart Neyns |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in glioblastoma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision